Lynda M. Vrooman to present findings from Dana-Farber/Boston Children’s clinical trial that led to FDA approval of novel drug for treatment of ALL in young patients
May 23, 2019
Dana-Farber/Boston Children’s Cancer and Blood Disorders
M. Vrooman, MD will present an abstract at the 2019 Annual Meeting
of the American Society of Clinical Oncology (ASCO).
The abstract, titled “Efficacy and toxicity of pegaspargase
and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma:
Results of DFCI 11-001” (Abstract # 10006)
will be presented at ASCO on Friday, May 31, from 2:45 p.m. to 5:45 p.m. (Pediatric
Oncology I; presentation time 4:45 p.m.)
Vrooman will present the findings from a multi-center clinical
trial led by Dana-Farber/Boston Children's investigators that contributed to
Food and Drug Administration (FDA) approval of a novel drug for acute lymphoblastic
The randomized trial for patients with newly diagnosed ALL
compared the efficacy and toxicity of calaspargase pegol, a novel pegylated
asparaginase formulation designed for longer activity in the body, with
standard-of-care pegaspargase. Given every three weeks rather than two weeks as
with the standard treatment, calaspargase pegol provided similar overall
survival, event-free survival, and safety profiles.
In December 2018, the FDA approved the use of calaspargase
pegol for the treatment of ALL in pediatric and young adult patients.
ASCO takes place in Chicago from May 31 to June 4. It is the
world’s largest clinical cancer research meeting, attracting more than 30,000
oncology professionals from around the world.